20/20 Biolabs vs OneMedNet
AIDX and ONMD side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AIDX and ONMD compare
OneMedNet is the larger company, worth 111 times as much as 20/20 Biolabs ($318M against $2.9M).
OneMedNet grew revenue faster over the last twelve months (217% versus 16.7% for 20/20 Biolabs).
20/20 Biolabs keeps more of each dollar of sales as profit, with a net margin of −183% compared with −584% at OneMedNet.
20/20 Biolabs scores higher on the StockData Score (6 against 3 for OneMedNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AIDX | ONMD |
|---|---|---|
| Size and price | ||
| Market cap | $2.9M | $318M |
| Share price | $0.225 | $5.37 |
| Change, 1 year | – | −65.4% |
| Change, 5 years | – | −94.7% |
| Beta (5Y) | – | −0.24 |
| Employees | 14 | 23 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 219× |
| P/B | 1.8× | – |
| FCF yield | – | −2.2% |
| Fair value | $0.553 | – |
| Margin of safety | 59.3% | – |
| Growth | ||
| Revenue growth (TTM) | 16.7% | 217% (better) |
| Profitability | ||
| Gross margin | 29.6% (better) | −68.8% |
| Operating margin | −163% (better) | −696% |
| Net margin | −183% (better) | −584% |
| FCF margin | – | −473% |
| Return on equity | −239% | – |
| Financial health | ||
| Interest coverage | −21.3× (better) | −307.0× |
| Current ratio | 1.99 (better) | 0.28 |
| Altman Z-score | −8.83 (better) | −99.19 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.2% | 10.2% |
| Held by insiders | 14.8% | 6.9% |
| Insider net buying, 12 months | – | $4.1M |
| Short interest, % of float | 0.52% | – |
Go deeper
- AIDX stock overview
- AIDX income statement
- AIDX valuation and score
- ONMD stock overview
- ONMD income statement
- ONMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.